Interest of the association azacitidine-lenalidomide as frontline therapy in high-risk myelodysplasia or acute myeloid leukemia with complex karyotype

Leukemia

Volumn 26, Issue 4, 2012, Pages 822-824

  Scherman, E ^a   Malak, S ^a   Perot, C ^a   Gorin, N C ^a   Rubio, M T ^a   Isnard, F ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; LENALIDOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; CELLULITIS; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DRUG DOSE REDUCTION; DRUG FATALITY; FEMALE; GRAFT VERSUS HOST REACTION; HEART ARRHYTHMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KARYOTYPE; KIDNEY FAILURE; LETTER; MALE; MULTIPLE CYCLE TREATMENT; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PRIORITY JOURNAL; SEPTIC SHOCK; THROMBOCYTOPENIA; THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; FEMALE; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RISK; THALIDOMIDE;

EID: 84859637209     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.284     Document Type: Letter

References (12)

1. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333. (Pubitemid 28452973)
2. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
3. Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E et al. Azacitidine for the treatment of patients with acute myeloid leukemia : Report of 82 patients enrolled in an italian compassionate program. Cancer; e-pub ahead of print 14 July 2011; doi:10.1002/cncr.26354.
4. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2009; 28: 562-569.
5. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011; 117: 403-411.
6. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465. (Pubitemid 44511560)
7. Ades L, Boehrer S, Prebet T, Beyne-Rauzy O, Legros L, Ravoet C et al. Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 2009; 113: 3947-3952.
8. Sekeres MA, List AF, Cuthbertson D, Paquette R, Ganetzky R, Latham D et al. Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010; 28: 2253-2258.
9. Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5675-5687.
10. Garcia-Manero G, Fenaux P. Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 2011; 29: 516-523.
11. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28: 605-613.
12. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009; 2: 36.